Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza

Project description

The objectives of the project is to provide technical support to the European Center for Disease Prevention and Control to build an infrastructure to allow regular monitoring of COVID-19 and influenza vaccine effectiveness over time, using a multi-country approach. The VEBIS platform includes vaccine effectiveness studies implemented in different settings.

Context situation

Vaccination plays a key role in the control of the coronavirus disease (COVID-19) pandemic and the lifting of some non-pharmaceutical interventions. Assessment of the real-world performance of the vaccines in the European Union is important to be able to adapt to European vaccination strategies.

Project activities

Hospital network measuring influenza and COVID-19 vaccine effectiveness

Multicenter test-negative design study.

Vaccine effectiveness and impact of COVID-19

vaccines through routinely collected exposure and outcome data using health registries.

COVID-19 vaccine effectiveness against SARS-CoV-2 infection among healthcare workers

Multicenter cohort study.

Primary care network measuring influenza and COVID-19 vaccine effectiveness

Multicenter test-negative design study.



    Scientific publications

    Protocol for a COVID-19 vaccine effectiveness study using health data registries, v.2.0

    Susana Monge Corella, Mario Fontán Vela (Instituto de Salud Carlos III, Spain), Irina Kislaya, Baltazar Nunes,
    Ausenda Machado, Patricia Soares and Constantino Caetano (Instituto Nacional de Saúde, Portugal), Cristina
    Buguri, Itziar Casado, Jesús Castilla, Iván Martínez-Baz (Instituto de Salud Pública y Laboral de Navarra), HanneDorthe Emborg, Katrin Finderup, Christian Holm Hansen, Bolette Søborg, Palle Valentiner-Branth (Statens Serum
    Institute, Denmark), Jostein Starrfelt, Hinta Meijerink, Anja Bråthen Kristoffersen (Norwegian Institute of Public
    Health), Joris van Loenhout, Toon Braeye, Izaak Van Evercooren, Pierre Hubin (Sciensano, Belgium), Brechje de
    Gier, Susan Hahné (Dutch National Institute for Public Health and the Environment – ​​RIVM-, the Netherlands), Ala'a
    AlKerwi, Susanne Schmitz (Ministry of Health, Directorate of Health, Service epidemiology and statistics,
    Luxembourg), Chiara Sacco, Alberto Mateo Urdiales, and Massimo Fabiani (Istituto Superiore di Sanità, Italy),
    Anthony Nardone, Alexis Sentís, Esther Kissling, James Humphreys, Marta Valenciano (Epiconcept, France).

    European Center for Disease Prevention and Control. Stockholm: ECDC; 2024

    Available here

    Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza – Version 3.0

    Liliana Antunes, Jenny Howard, Esther Kissling, Ruoran Li, Alain Moren, Anthony Nardone, Angie Rose, Marta Valenciano

    ECDC – Version 3.0

    Available here

    Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalization in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

    Antunes Liliana, Mazagatos Clara, Martínez-Baz Iván, Gomez Verónica, Borg Maria-Louise, Petrović Goranka, Duffy Róisín, Dufrasne François E, Dürrwald Ralf, Lazar Mihaela, Jancoriene Ligita, Oroszi Beatrix, Husa Petr, Howard Jennifer, Melo Aryse, Pozo Francisco , Pérez-Gimeno Gloria, Castilla Jesús, Machado Ausenda, Džiugytė Aušra, Karabuva Svjetlana, Fitzgerald Margaret, Fierens Sébastien, Tolksdorf Kristin, Popovici Silvia-Odette, Mickienė Auksė, Túri Gergő, Součková Lenka, Nicolay Nathalie, Rose Angela MC, on behalf of the European Hospital Vaccine Effectiveness Group.

    Euro Surveillance 2024;29(3):pii=2300708.

    Available here

    Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, v.2.0

    Camelia Savulescu, Esther Kissling, Anthony Nardone

    Stockholm: ECDC; 2022.

    Available here

    Generic protocol for ECDC studies of influenza vaccine effectiveness against confirmed infection using healthcare worker cohorts – version 2.0

    Camelia Savulescu, Esther Kissling, Anthony Nardone

    European Center for Disease Prevention and Control. Stockholm: ECDC; 2024.

    Available here

    Relative vaccine effectiveness against COVID-19 hospitalization in persons aged≥65 years: results from a VEBIS network, Europe, October 2021 to July 2023

    Fontán-Vela Mario, Kissling Esther, Nicolay Nathalie, Braeye Toon, Van Evercooren Izaak, Holm Hansen Christian, Emborg Hanne-Dorthe, Fabiani Massimo, Mateo-Urdiales Alberto, AlKerwi Ala'a, Schmitz Susanne, Castilla Jesús, Martínez-Baz Iván, de Gier Brechje, Hahné Susan , Meijerink Hinta, Starrfelt Jostein, Nunes Baltazar, Caetano Constantino, Derrough Tarik, Nardone Anthony, Monge Susana, VEBIS-Lot4 working group.

    Euro Surveillance 2024;29(1):pii=2300670

    Available here

    Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicenter study

    Maurel M, Pozo F, Pérez-Gimeno G, et al.

    Influenza Other Respiratory Viruses. 2024; 18(1):e13243. doi:10.1111/irv.13243

    Available here

    Vaccine effectiveness against COVID-19 hospitalization in adults (≥20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

    Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, Denayer S, Seyler L, Domegan L, Launay O, Machado A, Burgui C, Vaikutyte R, Niessen FA, Loghin II, Husa P, Aouali N, Panagiotakopoulos G, Tolksdorf K, Horváth JK, Howard J, Pozo F, Gallardo V, Nonković D, Džiugytė A, Bossuyt N, Demuyser T, Duffy R, Luong Nguyen LB, Kislaya I, Martínez-Baz I, Gefenaite G, Knol MJ , Popescu C, Součková L, Simon M, Michelaki S, Reiche J, Ferenczi A, Delgado-Sanz C, Lovrić Makarić Z, Cauchi JP, Barbezange C, Van Nedervelde E, O'Donnell J, Durier C, Guiomar R, Castilla J, Jonikaite I, Bruijning-Verhagen PC, Lazar M, Demlová R, Wirtz G, Amerali M, Dürrwald R, Kunstár MP, Kissling E, Bacci S, Valenciano M; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)

    Euro Surveillance 2023 Nov;28(47):2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187. PMID: 37997665; PMCID: PMC10668256.

    Available here

    Vaccine effectiveness against COVID-19 hospitalization in adults (≥20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

    Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Niessen FA, Machado A, Launay O, Denayer S, Seyler L, Baruch J, Burgui C, Loghin II, Domegan L, Vaikutytė R, Husa P, Panagiotakopoulos G, Aouali N, Dürrwald R, Howard J, Pozo F, Sastre-Palou B, Nonković D, Knol MJ, Kislaya I, Luong Nguyen LB, Bossuyt N, Demuyser T, Džiugytė A, Martínez-Baz I, Popescu C, Duffy R, Kuliešė M, Součková L, Michelaki S, Simon M, Reiche J, Otero-Barrós MT, Lovrić Makarić Z, Bruijning-Verhagen PC, Gomez V, Lesieur Z, Barbezange C, Van Nedervelde E, Borg ML, Castilla J, Lazar M , O'Donnell J, Jonikaitė I, Demlová R, Amerali M, Wirtz G, Tolksdorf K, Valenciano M, Bacci S, Kissling E; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors)

    Euro Surveillance 2023 Nov;28(47):2300186. doi: 10.2807/1560-7917.ES.2023.28.47.2300186. PMID: 37997666; PMCID: PMC10668259.

    Available here

    Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalization and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022

    Kislaya I, Sentis A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, AlKerwi A, Braeye T, Fontán-Vela M, Bacci S, Meijerink H, Castilla J, Emborg HD, Hansen CH, Schmitz S, Van Evercooren I, Valenciano M, Nardone A, Nicolay N, Monge S; VEBIS‐Lot4 working group.

    Influenza Other Respiratory Viruses. 2023 Nov;17(11):e13195. doi: 10.1111/irv.13195. PMID: 38019704; PMCID: PMC10682901.

    Available here

    Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – fourth update

    Jennifer Howard, Esther Kissling, Ruoran Li, Anthony Nardone, Angie Rose (Epiconcept)

    ECDC: Stockholm; 2023 March, 16

    Available here

    Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection, laboratoryconfirmed with SARS-CoV-2 or with seasonal influenza – Version 2.0

    Jenny Howard, Esther Kissling, Ruoran Li, Alain Moren, Anthony Nardone, Angie Rose, Marta Valenciano (Epiconcept)

    Stockholm: ECDC; 2023.January

    Available here

    European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 20 years and older, ECDC multi-country study – third update

    European Center for Disease Prevention and Control: Sabrina Bacci, Nathalie Nicolay.
    Epiconcept, Paris, France: Jennifer Howard, Esther Kissling, Anthony Nardone, Angie Rose

    ECDC: Stockholm; 2022 November 8.

    Available here

    COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data.

    Sridhar S, Fico A, Preza I, Hatibi I, Sulo J, Kissling E, Daja R, Ibrahim R, Lemos D, Rubin-Smith J, Schmid A, Vasili A, Valenciano M, Jorgensen P, Pebody R, Lafond KE, Katz MA, Bino S.

    BMJ Open 2022;12:e057741. doi:10.1136/bmjopen-2021-057741

    Available here

    European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update.

    European Center for Disease Prevention and Control.

    ECDC: Stockholm; 2022 January 20

    Available here

    Estimate of COVID-19 vaccine effectiveness against hospitalization in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

    Sentis A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, Castilla J, Nielsen KF, Hansen CH, Emborg HD, Nardone A, Derrough T, Valenciano M, Nunes B, Monge S, the VEBIS-Lot4 working group

    October 2021 to March 2022. Euro Surveillance. 2022;27(30):pii=2200551

    Available here

    European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update.

    European Center for Disease Prevention and Control.

    ECDC: Stockholm; 2022 Mar, 14.

    Available here

    Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicenter analysis, I-MOVE-COVID-19 and ECDC networks

    Kissling E, Hooiveld M, Martínez-Baz, Mazagatos C, William N, Vilcu AM, Kooijman MN, Ilić M, Domegan L, Machado A, de Lusignan S, Lazar M, Meijer A, Brytting M, Casado I, Larrauri A, Murray JL K, Behillil S, de Gier B, Mlinarić I, O'Donnell J, Rodrigues AP, Tsang R, Timnea O, de Lange M, Riess M, Castilla J, Pozo F, Hamilton M, Falchi A, Knol MJ, Kurečić Filipović S, Dunford L, Guiomar R, Cogdale J, Cherciu C Jansen T, Enkirch T, Basile L, Connell J, Gomez V Sandonis Martín V, Bacci S, Rose AMC, Pastore Celentano L, Valenciano M, I-MOVE-COVID-19 and ECDC primary care study teams

    July to August 2021. Euro Surveillance. 2022;27(21):pii=2101104

    Available here

    European Center for Disease Prevention and Control. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 65 years and older, ECDC multi-country study.

    European Center for Disease Prevention and Control.

    ECDC: Stockholm; 2021 October, 8.

    Available here

    Core protocol for ECDC studies of COVID19 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. Stockholm: ECDC; 2021 Oct, 8.

    Find all our scientific publications

    Central purchasing referencing

    Health data hosting

    We are Health Data Host (HDS) of a personal nature since 2012 with ISO 27001/HDS certification since 2019.

    Learn more

    Commitment and ethics

    Discover our commitments and values ​​in our charter